Intercept Pharmaceuticals Inc (NASDAQ:ICPT) insider Lisa Bright sold 253 shares of the business’s stock in a transaction on Friday, August 25th. The shares were sold at an average price of $111.31, for a total transaction of $28,161.43. Following the transaction, the insider now owns 23,324 shares of the company’s stock, valued at $2,596,194.44. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Lisa Bright also recently made the following trade(s):

  • On Wednesday, August 2nd, Lisa Bright sold 142 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $110.29, for a total transaction of $15,661.18.
  • On Monday, July 3rd, Lisa Bright sold 394 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $121.33, for a total transaction of $47,804.02.
  • On Thursday, June 1st, Lisa Bright sold 698 shares of Intercept Pharmaceuticals stock. The stock was sold at an average price of $110.73, for a total transaction of $77,289.54.

Intercept Pharmaceuticals Inc (NASDAQ:ICPT) traded up 0.51% during mid-day trading on Tuesday, reaching $112.58. 244,852 shares of the company’s stock traded hands. The firm’s market cap is $2.83 billion. Intercept Pharmaceuticals Inc has a one year low of $96.63 and a one year high of $172.95. The firm’s 50-day moving average price is $115.85 and its 200 day moving average price is $117.63.

Intercept Pharmaceuticals (NASDAQ:ICPT) last announced its earnings results on Monday, July 31st. The biopharmaceutical company reported ($3.46) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($3.62) by $0.16. The company had revenue of $30.89 million during the quarter, compared to analyst estimates of $27.50 million. Intercept Pharmaceuticals had a negative net margin of 280.26% and a negative return on equity of 169.39%. Intercept Pharmaceuticals’s revenue was up 459.6% compared to the same quarter last year. During the same quarter last year, the firm posted ($3.14) earnings per share. On average, equities analysts forecast that Intercept Pharmaceuticals Inc will post ($14.05) EPS for the current year.

TRADEMARK VIOLATION WARNING: “Intercept Pharmaceuticals Inc (ICPT) Insider Sells $28,161.43 in Stock” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/08/29/intercept-pharmaceuticals-inc-icpt-insider-sells-28161-43-in-stock.html.

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. PNC Financial Services Group Inc. raised its position in Intercept Pharmaceuticals by 0.7% in the first quarter. PNC Financial Services Group Inc. now owns 2,020 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 14 shares during the last quarter. Public Employees Retirement Association of Colorado raised its position in Intercept Pharmaceuticals by 1.1% in the second quarter. Public Employees Retirement Association of Colorado now owns 4,111 shares of the biopharmaceutical company’s stock valued at $498,000 after buying an additional 43 shares during the last quarter. Janney Montgomery Scott LLC raised its position in Intercept Pharmaceuticals by 1.8% in the second quarter. Janney Montgomery Scott LLC now owns 3,435 shares of the biopharmaceutical company’s stock valued at $416,000 after buying an additional 62 shares during the last quarter. WFG Advisors LP raised its position in Intercept Pharmaceuticals by 16.4% in the second quarter. WFG Advisors LP now owns 888 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 125 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Intercept Pharmaceuticals by 14.4% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,047 shares of the biopharmaceutical company’s stock valued at $118,000 after buying an additional 132 shares during the last quarter. 82.19% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently issued reports on ICPT. Cantor Fitzgerald reiterated an “underweight” rating and issued a $69.00 target price (up from $60.00) on shares of Intercept Pharmaceuticals in a research report on Tuesday, August 8th. Zacks Investment Research upgraded shares of Intercept Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, May 8th. Credit Suisse Group upped their target price on shares of Intercept Pharmaceuticals from $198.00 to $201.00 and gave the stock an “outperform” rating in a research report on Monday, May 15th. BidaskClub upgraded shares of Intercept Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, June 23rd. Finally, Jefferies Group LLC began coverage on shares of Intercept Pharmaceuticals in a research report on Monday, July 10th. They issued a “buy” rating and a $275.00 target price for the company. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $205.04.

Intercept Pharmaceuticals Company Profile

Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.

Insider Buying and Selling by Quarter for Intercept Pharmaceuticals (NASDAQ:ICPT)

Receive News & Ratings for Intercept Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.